AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01658410 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BQ-123
Description: BQ-123 (Clinalfa, Läufelfingen, Switzerland) Dosage: 15µmol in two equal amounts (7.5µmol); in the first and last cardioplegia Route: intracoronary
Study NCT01658410 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: NaCl
Description: NaCl, Route: intracoronary
Study NCT00808925 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exposure to heat
Description: Dressed in shorts and tennis shoes the subjects will be exposed to exercise-heat stress for 12 consecutive days (excluding Saturday). Daily exposure will last 120 min, under the controlled environmental conditions of 40oC and 40% relative humidity. The exercise will consist of walking on a treadmill at a pace of 5km/h and 2% incline.
Study NCT02964871 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sofia Fluorescent Immunoassay Analyzer Influenza A+B
Description: The Sofia Influenza A+B Fluorescent Immunoassay (FIA) uses advanced immunofluorescence-based lateral-flow technology to detect influenza A and influenza B viral nucleoprotein antigens.
Study NCT02964871 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Usual care
Description: Our team will discuss our interest in monitoring influenza antiviral treatment and prophylaxis courses, antibiotic courses, clinician and emergency room visits, respiratory infection-related hospitalizations, all-cause hospitalizations, and deaths during the anticipated 4-month influenza season over 3 years.
Study NCT02841046 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: cardiac index
Description: group cardiac index（CI） and group Stroke Volume Variation（SVV） are different treatment schemes of goal-directed fluid therapy guided by SVV and CI,group cardiac index with CI as the primary judgment.
Study NCT02841046 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stroke Volume Variation
Description: group cardiac index（CI） and group Stroke Volume Variation（SVV） are different treatment schemes of goal-directed fluid therapy guided by SVV and CI,group Stroke Volume Variation with the combination of SVV and CI as the primary judgment.
Study NCT02911831 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sodium Chloride
Study NCT03966430 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: damage control surgery
Description: 1. Emergency surgery stage, (a) the hybrid operating room restores mesenteric vascular patency. (b) excision of the necrotic intestine (c) retention of suspicious intestinal ducts, double stoma (d) establishment of catheter thrombolysis pathway (e) apply TAC to maintain open abdominal.~2. ICU phase, including (a) fluid resuscitation; (b) anti-infective and organ function support therapy; (c) continued local anticoagulation, thrombolysis (d) arrange planned re-laparotomy (e) early EN.~3. Definitive surgical procedures, including (a) Deterministic fascia closure or further removal of the necrotic intestine. (b) Intestinal stoma care and enteral nutrition support treatment. (c) An enterostomy was performed about 6 months after the first operation.
Study NCT03803826 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CRT-D re-programming
Description: The previously implanted, ineffective CRT-D is reprogrammed under supervision of Trans-Thoracic Echocardiography (TTE) to:~1. adjust the atrioventricular interval so that E and A waves do not overlap~2. the interventricular interval is subsequently optimized to yield maximum improvement of the sum of longitudinal+radial+circumferential strains.
Study NCT03803826 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Trans-Thoracic Echocardiography
Description: This intervention relates to the determination of strains and atrioventricular interval and supplies data for reprogramming the ineffective CRT-D~Transthoracic echocardiography performed to determine the left ventricular ejection fraction as an outcome measure is not considered intervention here (as it is also performed in the control group and that would cause an error cross-referencing.
Study NCT03966430 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: non-damage control surgery
Description: The patients are diagnosed with AMI and treated for mesenteric thrombosis and ischemic bowel.~1. The patient retains the endoluminal catheter after the DSA was diagnosed as AMI.~2. After diagnosis, the operation is performed in the general operating room, and the intestinal fistula double or the anastomosis is performed according to the judgment of the surgeon.~3. After the operation, re-laparotomy is performed on demand.
Study NCT00809198 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sodium Hyaluronate
Study NCT00809198 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Carboxymethylcellulose sodium
Study NCT03769493 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mobile After-Care Support (MACS) app
Description: The MACS app assesses and intervenes by fostering increased treatment adherence (medication/appointments) and self-coping with illness (active, planned, problem-solving focused) to reduce symptoms and improve functioning. Additionally, MACS encourages participants who are already reporting adherence and healthy coping by using positive reinforcement strategies to maintain efforts and promote additional goal setting. MACS app strategies are linked to participants' specific assessment responses, allowing for a highly personalized self-management intervention experience. The MACS app provides interactive exercises delivered by the device designed to teach patients coping skills that they can use now and in the future.
Study NCT02383615 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Saphenous nerve block
Description: Ultrasound guided saphenous nerve blocks with 0.5% Ropivacaine for patients undergoing elective foot and ankle surgery for post-operative pain relief.
Study NCT00049569 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Description: Given IT
Study NCT00049569 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Description: Given IT
Study NCT00049569 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate
Description: Given IV
Study NCT00049569 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone
Description: Given PO
Study NCT02954172 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab in Combination With Paclitaxel/Carboplatin
Description: Drug Bevacizumab15mg/kg in combination with Paclitaxel/Carboplatin 6 cycles then maintains at 7.5 mg/kg
Study NCT00049569 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pegaspargase
Description: Given IM
Study NCT02954172 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IBI305 in Combination with Paclitaxel/Carboplatin
Description: Drug IBI305 15mg/kg in combination with Paclitaxel/Carboplatin 6 cycles then maintains at 7.5 mg/kg
Study NCT00275548 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Pegasys
Description: 135-180 micrograms administered sc once weekly
Study NCT00275548 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Copegus
Description: 400-1200 mg/day for 48 weeks
Study NCT01032109 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: A single intravitreal injection of 1.25 mg of bevacizumab (0.05 mL of solution prepared from Avastin, 100 mg/4 mL vial) was performed within 2 weeks after PDT treatment.
Study NCT00049569 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride
Description: Given IV
Study NCT02657785 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: R-IDARAM plus intrathecal chemotherapy
Description: R-IDARAM comprised of rituximab 375 mg/m2 (day 1), idarubicin 10 mg/m2(day 2 and 3); dexamethasone 100 mg/m2 (12 h.infusion in day 2, 3 and 4); cytarabine 1 g/m2 (1 h. infusion in day 2 and 3); methotrexate 2 g/m2 (6 h. infusion in day 4 with folinic acid rescue). Intrathecal Immunochemotherapy comprised of rituximab 10mg, MTX 15mg, dexamethasone 5mg and Ara-c 50mg once a week.
Study NCT03882268 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MIYCN interventions
Description: 1. Capacity building for health providers and nutrition counselors (training on MIYCN SBCC from A\&T).~2. Dedicated room for MIYCN counseling at health facilities with standardized layouts, displays of government IYCF logo, and other specifications.~3. Availability of standardized MIYCN-specific BCC materials and job aids.~4. Standardized MIYCN counseling services (counseling on diet diversity and quantity, IFA and calcium supplementation, weight gain monitoring, exclusive and early initiation of breastfeeding, complementary feeding, and water, sanitation and health) provided by a dedicated MIYCN counselor hired by A\&T.~5. Dedicated community worker hired by A\&T to identify and mobilize beneficiaries needing services in the community (via satellite clinic outreach, distribute MIYCN flyers, and provision of MIYCN education via phone or home visits).~6. Supportive supervision of MIYCN counselors and community workers by program and facility managers, and field supervisors.
Study NCT02978599 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AVL-3288
Description: daily for 5 days
Study NCT02978599 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: daily for 5 days
Study NCT02562664 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CC
Description: 100 mg clomiphene Citrate (Clomid , global Napi , Egypt) CC tablets taken from day 3 to day 7 of the cycle
Study NCT00049569 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: imatinib mesylate
Description: Given PO
Study NCT02562664 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo tablets
Description: Placebo tablets taken twice daily continuously for three cycles.
Study NCT02562664 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: wMetformin (Cidophage , Amon , Egypt) 500 mg twice daily continuously for three cycles.
Study NCT02659397 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ETC-1002
Description: Blinded ETC-1002 180 mg tablet once daily for 4 weeks (Weeks 1 to 4)
Study NCT02659397 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: Atorvastatin 80 mg tablet once daily for 8 weeks (Weeks -4 to 4)
Study NCT02659397 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Atorvastatin
Description: Atorvastatin 80 mg tablet once daily for 8 weeks (Weeks -4 to 4)
Study NCT02659397 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Blinded ETC-1002-matched placebo tablet once daily for 4 weeks (Weeks 1 to 4)
Study NCT02228980 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Shenzhen trivalent influenza vaccine (split virion, inactivated) North Hemisphere (NH) formulation
Description: 0.25 mL Intramuscular (2 doses given 28 days apart)
Study NCT02228980 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Shenzhen trivalent influenza vaccine (split virion, inactivated) North Hemisphere (NH) formulation
Description: 0.5 mL Intramuscular
Study NCT00049569 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given IV
Study NCT00049569 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Description: Given IV
Study NCT02948517 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Time restricted feeding
Description: Time restricted feeding
Study NCT00522769 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behavioral Therapy
Description: Girls enrolled in the study will either receive the 6-20 session CBT intervention at the time of enrollment or 6 months after they enroll. Assessments including questions about eating behaviors, mood, and general functioning are given on enrollment in the study, and 3- and 6-months following enrollment (also at 9- and 12-months for those in the delayed treatment condition
Study NCT00049569 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Description: Given SC
Study NCT00049569 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin calcium
Description: Given IV
Study NCT00522769 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy
Description: Girls enrolled in the study will either receive the 6-20 session CBT intervention at the time of enrollment or 6 months after they enroll. Assessments including questions about eating behaviors, mood, and general functioning are given on enrollment in the study, and 3- and 6-months following enrollment (also at 9- and 12-months for those in the delayed treatment condition
Study NCT00049569 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: asparaginase
Description: Given IM
Study NCT00049569 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: therapeutic hydrocortisone
Description: Given IT
Study NCT01242787 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LB80380
Description: Optimal dose of LB80380, by oral for 48 weeks (optimal dose will be chosen early 2011 based on the results of LG-BVCL007 study)
Study NCT01242787 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Entecavir 0.5 mg
Description: Entecavir 0.5 mg, by oral for 48 weeks
Study NCT02205645 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FibroFix™ Meniscus scaffold
Description: The test article for this study is the FibroFix™ Meniscus scaffold supplied by Orthox Ltd. The FibroFix™ Meniscus scaffold has been developed for repair of defects of the meniscus.~The FibroFix™ Meniscus scaffold used in this study is a silk derived product developed to functionally replace the excised unstable meniscus following a meniscal tear.
Study NCT04800497 — intervention group
Intervention type: PROCEDURE
Intervention: Hepatic resection
Description: Hepatic resection for HCC
Study NCT06415630 — intervention group
Intervention type: PROCEDURE
Intervention: Type A aortic dissection surgery
Description: Patients with type A aortic dissection undergone surgery.
Study NCT04346719 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 10 kHz stimulation (Myomed 932, Enraf-Nonius)
Description: A charge-balanced, symmetric, biphasic sinusoidal current without modulation will be delivered at a frequency of 10 kHz. The stimulation intensity will be defined as that sufficient to produce a strong but comfortable sensation, just below motor threshold, over the median nerve through the electrotherapy device Myomed 932. (Enraf-Nonius, Delft,Netherlands)
Study NCT03575169 — intervention group
Intervention type: DEVICE
Intervention: BIS Monitor
Description: Unilateral BIS electrode
Study NCT01138735 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: adapalene/benzoyl peroxide
Description: daily topical application for 12 weeks
Study NCT01138735 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Topical Gel Vehicle
Description: daily topical application for 12 weeks
Study NCT03913039 — intervention group
Intervention type: PROCEDURE
Intervention: Transperineal biopsy Protocol
Description: 1. Transperineal biopsy approach with avoidance of rectal flora~2. MRI-ultrasound fusion-guided biopsies with reduced number of biopsy cores, where clinically indicated~3. Rectal swab to identify the presence of fluoroquinolone resistant (FQR) bacteria~4. Multi-antibiotic prophylaxis~5. Urine culture, prostate tissue culture and rectal swab culture to define contemporary, region-specific antibiotic resistance patterns.
Study NCT04553718 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: experimental group
Description: provide mHealth program, which has pregnant women using wearable device and app
Study NCT04346719 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 20 kHz stimulation (Myomed 932, Enraf-Nonius)
Description: A charge-balanced, symmetric, biphasic sinusoidal current without modulation will be delivered at a frequency of 20 kHz. The stimulation intensity will be defined as that sufficient to produce a strong but comfortable sensation, just below motor threshold, over the median nerve through the electrotherapy device Myomed 932. (Enraf-Nonius, Delft,Netherlands)
Study NCT04346719 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham stimulation (Myomed 932, Enraf-Nonius)
Description: Sham stimulation will be delivered at a frequency of 10 kHz only during the first 30 seconds.
Study NCT02660983 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donepezil hydrochloride
Study NCT02660983 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Donepezil matching placebo
Study NCT00336648 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avastin (Bevacizumab)
Description: 10mg/kg by vein (IV) on Days 1, 2, 15 and 29 the adjuvant therapy every two weeks starting approximately 6 weeks after surgery for three months.
Study NCT00336648 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: 400 mg/m2 IV once a week on Days 1, 2, 8,15, 22, 29, 36 +/-2 days (Saturdays)
Study NCT00336648 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Day 3 +/-2 days (Monday) Start Radiation therapy, Mon -Fri x 28 days; 50.4 Gy prescribed to the 95% isodose at 1.8 Gy/fraction (28 fractions)
Study NCT01756703 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MT-3995 Low
Description: MT-3995 Low dose for 8 weeks
Study NCT01756703 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MT-3995 High
Description: MT-3995 High dose for 8 weeks
Study NCT01756703 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for 8 weeks
Study NCT05622149 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diet Only
Description: Food tracking based on macronutrient goals.
Study NCT05622149 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Training Only
Description: Subjects completed 16 weeks of supervised resistance training
Study NCT03464539 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: PG low molecular weight chitosan
Description: The product 1000 mg of Polyglucosamine was administered three times per day before and in between main meals
Study NCT03519191 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Healthy Relationships Education (HRE)
Description: Healthy Relationships and Economic Pathways involves formal classes in Healthy Relationship Education (HRE), comprehensive case management, and support services and referrals to services.
Study NCT03519191 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: HRE+Technology Bootcamp
Description: HRE + Technology Bootcamp involves formal classes in Healthy Relationships Education (HRE), comprehensive case management, support services and referral to services, 6-week intensive website and professional development training, and paid work experience developing a website for a local small business and mentorship.
Study NCT04103788 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: 95% Curcuminoid Powder
Description: 1200 mg curcuminoids
Study NCT04103788 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: CurQ+
Description: 400 mg curcuminoids + coconut oil + polysorbate
Study NCT01877252 — intervention group
Intervention type: PROCEDURE
Intervention: Surgical revascularization
Study NCT01877252 — intervention group
Intervention type: PROCEDURE
Intervention: Endovascular revascularization
Study NCT01877252 — intervention group
Intervention type: OTHER
Intervention: No vascular intervention
Study NCT02453672 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SB8
Description: SB8, proposed bevacizumab biosimilar
Study NCT02453672 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: EU sourced Avastin®
Description: EU sourced Avastin® (bevacizumab, Roche Registration Ltd.)
Study NCT02453672 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: US Sourced Avastin®
Description: US Sourced Avastin® (bevacizumab, Roche Registration Ltd.)
Study NCT00379301 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Radiofrequency ablation
Description: Special catheters are inserted into blood vessels in the groin, then advanced into the left atrium of the heart. Radiofrequency (heat) energy is applied to small areas of heart tissue where electrical impulses that generate AF are found.
Study NCT05622149 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diet plus Training
Description: Food tracking plus resistance training.
Study NCT02252263 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elotuzumab
Study NCT02252263 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lirilumab
Study NCT02252263 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Urelumab
Study NCT01066377 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Prebiotic and probiotic mix
Description: The probiotic strain will be Bifidobacterium longum bv. infantis CCUG 52486 (10\^8 - 10\^9 live bacteria per day), which was originally isolated from healthy elderly subjects, and which has been demonstrated to have particular ecological fitness and anti-pathogenic effects in vitro. A suitable prebiotic (8g/day) will be selected on the basis of ability to promote optimal growth and survival of this probiotic (inulin, fructooligosaccharides \[FOS\], galactooligosaccharides\[GOS\] and xylooligosaccharides\[XOS\] will be tested).